FOLX Health Review

FOLX Health — Provider Profile

Overview

FOLX Health is a telehealth platform founded in 2020 and purpose-built to serve LGBTQ+ patients. Its clinical services span gender-affirming hormone therapy, sexual health, primary care, and weight management including GLP-1 prescriptions. The platform was designed to function as a culturally competent, stigma-free alternative to conventional healthcare settings — environments where LGBTQ+ patients frequently report experiences of discrimination, misgendering, and inadequate care.

The clinical case for LGBTQ+-specific weight management care is more substantive than it might appear on the surface. In transgender patients, gender-affirming hormone therapy (GAHT) meaningfully interacts with metabolic function: estrogen therapy in trans women tends to increase fat mass and redistribute adiposity; testosterone therapy in trans men tends to shift lean-to-fat ratios and alter cardiovascular risk profiles. These interactions are clinically relevant for GLP-1 prescribing — dosing considerations, monitoring parameters, and cardiovascular risk assessment should account for GAHT status. A general-purpose GLP-1 telehealth platform staffed by clinicians without LGBTQ+ training may not evaluate these interactions. FOLX's providers are specifically trained to do so.

As of April 2026, patients should verify FOLX's current GLP-1 formulary directly at folxhealth.com. Compounded semaglutide lost its FDA shortage exemption in February 2025 following FDA's removal of semaglutide from the drug shortage list, which constrained the ability of compounding pharmacies to legally produce it. Platforms that had been offering compounded semaglutide were required to transition patients to FDA-approved branded formulations or tirzepatide. Any platform offering compounded semaglutide after that date should be approached with caution, and patients should confirm the regulatory status of any compounded formulation before use.

Medications Offered

• GLP-1 receptor agonists for weight management (verify current formulary at folxhealth.com)
• Estradiol (oral, patch, injectable, gel) for gender-affirming hormone therapy
• Testosterone (injectable, topical) for gender-affirming hormone therapy
• Anti-androgens (spironolactone, bicalutamide) as appropriate
• Sexual health medications (PrEP, PEP, erectile dysfunction, STI treatment)
• Primary care medications as clinically indicated

Pricing

Pricing varies by service and medication. Verify current rates at folxhealth.com. The membership fee covers clinical access; medications are priced separately. Patients should ask specifically about GLP-1 formulary and pricing during intake given the regulatory changes to compounded semaglutide in 2025.

States Served

FOLX operates across a substantial number of U.S. states. Coverage for hormone therapy and weight management services may differ by state due to varying controlled substance regulations and licensure requirements. Verify availability for your specific state and service type at folxhealth.com.

Insurance

• Insurance not consistently accepted; primarily cash-pay
• Some services may be billable depending on patient's plan; verify with insurer
• HSA/FSA may apply for eligible services
• PrEP may be available at low or no cost through manufacturer assistance programs

Consultation Process

Model: Video and asynchronous consultations with LGBTQ+-trained clinicians; ongoing messaging support

1. Complete intake covering gender identity, current medications (including GAHT if applicable), health goals, and relevant history
2. Initial video consultation with a clinician familiar with LGBTQ+ health considerations
3. Labs ordered or reviewed — includes metabolic panel, hormone levels if on GAHT, cardiovascular markers as appropriate
4. Treatment plan developed; GLP-1 prescribing considers GAHT status and any interactions
5. Ongoing follow-ups for dose adjustments and monitoring; GAHT and weight management tracked together where applicable

Pros

• LGBTQ+-trained providers who understand how gender-affirming hormone therapy interacts with metabolic health and GLP-1 prescribing
• Culturally competent environment — patients are not required to explain or justify their identity to receive care
• Combines gender-affirming care and weight management in a single platform, reducing the need to manage multiple providers
• Sexual health services (PrEP, STI treatment) available alongside weight management — meaningful for patients seeking consolidated care
• Asynchronous messaging option reduces friction for patients with variable schedules
• Founded specifically for LGBTQ+ patients, not a retrofit of a heteronormative platform

Cons

• Primarily cash-pay; insurance acceptance is limited, making it more expensive out-of-pocket than some competitors
• GLP-1 formulary should be verified given the 2025 compounded semaglutide regulatory changes — patients should confirm they are receiving a legally dispensed formulation
• Weight management is one service among many; patients seeking intensive, dedicated obesity medicine support may find more depth at weight-focused platforms
• State coverage variability affects availability of specific services, particularly hormone therapy
• The breadth of services means no single specialization is as deep as a condition-specific platform

Best For

LGBTQ+ patients — particularly transgender and nonbinary individuals — who want weight management and GLP-1 therapy from providers who understand their full clinical picture, including the metabolic and cardiovascular implications of gender-affirming hormone therapy. Also appropriate for LGBTQ+ patients who have had negative experiences in conventional healthcare settings and want a clinically competent environment where their identity is not a barrier to accessing straightforward medical care.

Editorial Verdict

FOLX Health addresses a real gap in the telehealth market. The default assumption in most GLP-1 platforms is a cisgender patient with no hormonal complicating factors. For transgender patients on estrogen or testosterone therapy, that assumption can lead to inadequate monitoring and missed clinical context. FOLX's model — clinicians trained in LGBTQ+ health who can manage hormone therapy and GLP-1 prescribing together — is a more appropriate clinical structure for this population.

The cash-pay model is the primary friction point. Most LGBTQ+ patients face the same economic constraints as the broader population, and the lack of insurance acceptance limits accessibility. Patients who can afford out-of-pocket costs will likely find the clinical environment and provider competence worth it relative to using a generic platform while separately managing GAHT through another provider.

The regulatory note on compounded semaglutide deserves emphasis. As of early 2025, compounded semaglutide can no longer be legally produced under the shortage exemption, and patients should verify they are receiving an FDA-approved branded formulation or a legally dispensed alternative. This applies to any telehealth platform, not only FOLX — but it is worth confirming explicitly during intake.

Related Content

• Who Qualifies for GLP-1 Medications?
• How Much Does Semaglutide Cost?
• How Much Does Tirzepatide Cost?